Joseph D. Keegan - Oct 26, 2023 Form 4 Insider Report for BIO-TECHNE Corp (TECH)

Role
Director
Signature
/s/ Andrew Nick as Attorney-in-Fact for Joseph D. Keegan pursuant to Power of Attorney previously filed
Stock symbol
TECH
Transactions as of
Oct 26, 2023
Transactions value $
$0
Form type
4
Date filed
10/30/2023, 04:42 PM
Previous filing
Oct 31, 2022
Next filing
Oct 28, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TECH Common Stock Award $0 +1.63K +15.21% $0.00 12.3K Oct 26, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TECH Stock Options (Right to Buy) Award $0 +3.94K $0.00 3.94K Oct 26, 2023 Common Stock 3.94K $61.51 Direct F1
holding TECH Stock Options (Right to Buy) 12.5K Oct 26, 2023 Common Stock 12.5K $31.26 Direct
holding TECH Stock Options (Right to Buy) 7.59K Oct 26, 2023 Common Stock 7.59K $44.96 Direct
holding TECH Stock Options (Right to Buy) 8.04K Oct 26, 2023 Common Stock 8.04K $50.41 Direct
holding TECH Stock Options (Right to Buy) 6.03K Oct 26, 2023 Common Stock 6.03K $63.92 Direct
holding TECH Stock Options (Right to Buy) 2.53K Oct 26, 2023 Common Stock 2.53K $128.81 Direct
holding TECH Stock Options (Right to Buy) 3.46K Oct 26, 2023 Common Stock 3.46K $73.94 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests on the earlier of the one year anniversary of the grant date (10/26/2023) or the date of Bio-Techne's 2024 annual meeting of shareholders.

Remarks:

On November 28, 2022, the Company completed a four-for-one stock split. All common stock amounts and exercise prices in the filing relating to securities acquired prior to November 28, 2022 have been adjusted to reflect the four-for-one stock split.